News
-
-
-
PRESS RELEASE
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
NanoViricides, Inc. highlights the strong effectiveness of its broad-spectrum antiviral drug NV-387 against various viruses. Expected to drive significant valuation and market share, leading to rapid regulatory approvals and early revenues -
-
-
PRESS RELEASE
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
NanoViricides, Inc., a leading global pioneer in broad-spectrum antivirals, achieves significant success in developing a drug against Measles with NV-387. The drug shows strong antiviral effectiveness in recent studies -
-
-
PRESS RELEASE
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
NanoViricides, Inc. comments on WHO's extension of the MPox Public Health Emergency of International Concern and highlights the development of NV-387, a potential broad-spectrum antiviral for MPOX treatment -
